secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001641172-25-026143
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences moves HQ to Cambridge, MA; advances EB-003 toward IND in 2026
--------------------------------------------------------------------------------

- Effective Sept 2, 2025, principal executive offices changed to 245 First Street, 18th Floor, Cambridge, MA 02142.
- Relocation aims to leverage Boston biotech hub for talent, collaboration, and capital access.
- Lead candidate EB-003 (dual 5-HT2A/5-HT1B agonist) progressing toward IND; first-in-human trial anticipated in 2026.
- EB-003 designed to provide neuroplastogenic benefits without hallucinatory effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000164117225026143/0001641172-25-026143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000164117225026143/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-026143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer